Maili Bergman
Plus aucun poste en cours
Profil
Maili Bergman worked as a Senior Vice President of Investor Relations at Live Nation Entertainment, Inc., Vice President of Investor Relations at Guess?, Inc., Director of Investor Relations at Abraxis BioScience, Inc., and Director of the Los Angeles chapter at the National Investor Relations Institute.
She obtained an undergraduate degree from the University of Southern California.
Anciens postes connus de Maili Bergman
| Sociétés | Poste | Fin |
|---|---|---|
| GUESS?, INC. | Investor Relations Contact | - |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Investor Relations Contact | - |
National Investor Relations Institute
 National Investor Relations Institute Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA. | Corporate Officer/Principal | - |
| LIVE NATION ENTERTAINMENT, INC. | Investor Relations Contact | - |
Formation de Maili Bergman
| University of Southern California | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| LIVE NATION ENTERTAINMENT, INC. | Consumer Services |
| GUESS?, INC. | Consumer Non-Durables |
| Entreprise privées | 2 |
|---|---|
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
National Investor Relations Institute
National Investor Relations Institute Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA. | Commercial Services |